ANRO Alto Neuroscience
- 12.360
- +0.080+0.65%
Alto Neuroscience News
Express News | Alto Neuroscience Names Michael Hanley As COO
Express News | Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
Buy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS Treatment
TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience | 10-Q: Quarterly report
Express News | Alto Neuroscience Inc: Qtrly Shr Loss $0.76
Express News | Alto Neuroscience Q1 2024 GAAP EPS $(0.76) Misses $(0.47) Estimate
Alto Neuroscience 1Q Loss/Shr 76c >ANRO
Alto Neuroscience 1Q Loss/Shr 76c >ANRO
Express News | Alto Neuroscience Inc: Patient Enrollment on Track Across Phase 2B Mdd Studies for Alto-100 and Alto-300
Express News | Alto Neuroscience Inc: Strong Cash Position of Approximately $206 Mln Expected to Support Planned Operations Into 2027
Express News | Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
– Breadth of Alto's pipeline and Precision Psychiatry Platform will be highlighted across twelve posters and presentations at the Society of Biological Psychiatry and American Society of Clinical
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Recently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with
Alto Neuroscience Schizophrenia Treatment Shows Good Phase 1 Results
Express News | Alto Neuroscience Announces Positive Phase 1 Results For ALTO-101, A Novel PDE4 Inhibitor In Development For Schizophrenia
Express News | Alto Neuroscience Inc - Novel Transdermal Formulation Delivered Significantly Greater Drug Exposure, Fewer Adverse Events Typically Associated With Pde4 Inhibitors
Express News | Alto Neuroscience Inc - Proof-of-Concept Study in Cognitive Impairment Associated With Schizophrenia (Cias) to Be Initiated in First Half of 2024
Express News | Alto Neuroscience Inc - Alto-101 Demonstrated a Favorable Pharmacokinetic and Tolerability Profile
Express News | Alto Neuroscience Announces Positive Phase 1 Results for Alto-101, a Novel Pde4 Inhibitor in Development for Schizophrenia
Express News | Alto Neuroscience Has Initiated Phase 2 Study Of ALTO-203 In Major Depressive Disorder; Alto Expects To Report Topline Data From This Study In 1H Of 2025
Analysis
Price Target
No Data
